Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey

View ORCID ProfileDavid Emes, View ORCID ProfileAnke Hüls, Nicole Baumer, View ORCID ProfileMara Dierssen, Shiela Puri, Lauren Russel, Stephanie L. Sherman, View ORCID ProfileAndre Strydom, View ORCID ProfileStefania Bargagna, Ana Cláudia Brandão, View ORCID ProfileAlberto C.S. Costa, Brian Allen Chicoine, View ORCID ProfileSujay Ghosh, View ORCID ProfileAnne-Sophie Rebillat, View ORCID ProfileGiuseppina Sgandurra, View ORCID ProfileDiletta Valentini, View ORCID ProfileTilman R. Rohrer, View ORCID ProfileJohannes Levin, View ORCID ProfileMonica Lakhanpaul, The Trisomy 21 Research Society COVID-19 Initiative
doi: https://doi.org/10.1101/2021.06.25.21259525
David Emes
1Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Emes
Anke Hüls
2Department of Epidemiology and Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anke Hüls
Nicole Baumer
3Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mara Dierssen
4Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Doctor Aiguader 88,Barcelona, Spain. Universitat Pompeu Fabra (UPF), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mara Dierssen
Shiela Puri
5Down Syndrome Medical Interest Group UK. Leeds Community Healthcare NHS Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Russel
6Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie L. Sherman
7Department of Human Genetics, School of Medicine, Emory University, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andre Strydom
8Institute of Psychiatry, Psychology, and Neuroscience, Department of Forensic and Neurodevelopmental Sciences, King’s College London, London, United Kingdom; The London Down Syndrome (LonDownS) Consortium, London, United Kingdom; South London and the Maudsley NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andre Strydom
Stefania Bargagna
9Fondazione Stella Maris IRCCS, Pisa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefania Bargagna
Ana Cláudia Brandão
10Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto C.S. Costa
11Departments of Pediatrics and of Psychiatry, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alberto C.S. Costa
Brian Allen Chicoine
12Advocate Medical Group Adult Down Syndrome Center, Park Ridge, IL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sujay Ghosh
13Cytogenetics and Genomics Research Unit. Department of Zoology, University of Calcutta.Kolkata. West Bengal, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sujay Ghosh
Anne-Sophie Rebillat
14Institut Jérôme Lejeune, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne-Sophie Rebillat
Giuseppina Sgandurra
15Department of Developmental Neuroscience, IRCCS Fondazione Stella Maris, Pisa, Italy; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giuseppina Sgandurra
Diletta Valentini
16Pediatric Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Diletta Valentini
Tilman R. Rohrer
17Division of Pediatric Endocrinology, Saarland University Medical Center, Homburg/Saar, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tilman R. Rohrer
Johannes Levin
18Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany. German Center for Neurodegenerative Diseases, site Munich. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Johannes Levin
Monica Lakhanpaul
19UCL- Great Ormond Street Institute of Child Health, London, United Kingdom; Whittington NHS Trust, London, United Kingdom; Down Syndrome Medical Interest Group, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Monica Lakhanpaul
  • For correspondence: m.lakhanpaul@ucl.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Adults with Down syndrome (DS) are at higher risk for severe outcomes of coronavirus disease 2019 (COVID-19), but further evidence is required to determine the exact risks for children with DS. The clinical features and epidemiological characteristics of COVID-19 in children with DS, and risk factors for severe outcomes, must be established to inform COVID-19 shielding advice and vaccination priority.

Objective To determine risk factors for a severe course of COVID-19 in pediatric DS patients and to compare the prevalence of severe COVID-19 between pediatric patients with and without DS.

Design This retrospective cohort study included pediatric cases (aged <18 years) with DS from the Trisomy 21 Research Society international survey and pediatric cases from the general population published by the US Centers for Disease Control and Prevention (COVID-NET) collected during the first wave of the COVID-19 pandemic (controls).

Setting Cohorts included 328 children with DS (127 hospitalized, 39%) and 224 children without DS (all hospitalized) with COVID-19. Of the pediatric DS patients, 64.1% were from low-to-middle-income countries (LMICs), and 35.9% from high-income countries (HICs).

Participants Clinicians, family members, or caregivers completed the survey on behalf of children with DS affected by COVID-19.

Results Among the 328 COVID-19 patients with DS; older age, obesity, and epilepsy were significant risk factors for hospitalization; and age and thyroid disorder were significant risk factors for acute respiratory distress syndrome. The 127 hospitalized COVID-19 patients with DS had a higher incidence of cough, fever, nasal signs and shortness of breath than controls. Compared with controls, hospitalized children with DS (especially those from LMICs) had a higher prevalence of COVID-19-related medical complications (pneumonia, ARDS, acute renal failure).

Conclusions and relevance Children with DS are at higher risk for severe COVID-19 than the general pediatric population. Efforts should be made to monitor the health of children and young people with DS during the ongoing pandemic and to report any COVID-19 signs and symptoms in a timely manner, especially for those who have comorbidities which are risk factors for severe COVID-19. When vaccination rollout for pediatric populations begins, children with DS should be prioritised.

Question What are the epidemiological and clinical characteristics of coronavirus disease 2019 (COVID-19) in paediatric patients with Down syndrome (DS)?

Findings Hospitalised COVID-19 patients <18 years of age with DS from a range of countries had a higher incidence of respiratory symptoms, fever, and several medical complications from COVID-19 than patients without DS <18 years from the United States (US). Older age, obesity, and epilepsy were significant risk factors for hospitalisation among paediatric COVID-19 patients with DS; and age and thyroid disorder were significant risk factors for acute respiratory distress syndrome. Mortality rates were low in all paediatric COVID-19 patients (with and without DS), in contrast to previous findings in adults with DS (who exhibit higher mortality than those without DS).

Significance Children with DS are at increased risk for more severe presentations of COVID-19. Efforts should be made to ensure comprehensive and early detection of COVID-19 in this population, and to identify children with DS who present comorbidities that pose a risk for a severe course of COVID-19. Children with DS should be prioritised for COVID-19 vaccination as part of children’s vaccination programmes.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

No trial ID as this manuscript uses survey data

Funding Statement

No external funding was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Spain The study was approved by the Hospital del Mar ethics committee (CEIC Parc de Salut Mar, CEim 2020/9197) United Kingdom The T21RS survey was approved by the Health research agency (HRA) 20/HRA/2452. The ISARIC4C analysis was approved by the study board (IDAMAC) Brazil This study was approved by the Brazilian Federal Ethics Committee (CONEP, CAAE: 30847520.8.0000.0071) Emory University, U.S.A. This study was deemed exempt from human subjects research under 45 CFR 46.104(d)(2i) (IRB ID: STUDY00000386) Italy The study was approved by the Bambino Gesu childrens Hospital Ethics Committee (2091_OPBG_2020) Advocate Health Care Institutional Review Board Determined to have Exempt Status IRB# 20-151ET France This study was approved by CPP Sud Mediterranee IV dated 29/04/2020 (ID RCB 2020-A00940-39) Ludwig-Maximilians-Universitaet (LMU), Munich, Germany Determined to have Exempt Status (IRB ID: 20-573 KB) India The study was approved by the Ethics Committee constituted by the University of Calcutta (CU/BIOETHICS/HUMAN/2306/3044/2020)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data used are drawn from international surveys, which are cited and made accessible to readers

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 02, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey
David Emes, Anke Hüls, Nicole Baumer, Mara Dierssen, Shiela Puri, Lauren Russel, Stephanie L. Sherman, Andre Strydom, Stefania Bargagna, Ana Cláudia Brandão, Alberto C.S. Costa, Brian Allen Chicoine, Sujay Ghosh, Anne-Sophie Rebillat, Giuseppina Sgandurra, Diletta Valentini, Tilman R. Rohrer, Johannes Levin, Monica Lakhanpaul, The Trisomy 21 Research Society COVID-19 Initiative
medRxiv 2021.06.25.21259525; doi: https://doi.org/10.1101/2021.06.25.21259525
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey
David Emes, Anke Hüls, Nicole Baumer, Mara Dierssen, Shiela Puri, Lauren Russel, Stephanie L. Sherman, Andre Strydom, Stefania Bargagna, Ana Cláudia Brandão, Alberto C.S. Costa, Brian Allen Chicoine, Sujay Ghosh, Anne-Sophie Rebillat, Giuseppina Sgandurra, Diletta Valentini, Tilman R. Rohrer, Johannes Levin, Monica Lakhanpaul, The Trisomy 21 Research Society COVID-19 Initiative
medRxiv 2021.06.25.21259525; doi: https://doi.org/10.1101/2021.06.25.21259525

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (221)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)